ALLOX closes $10.5m financing to scale allosteric discovery platform
ALLOX has announced the successful closing of its $10.5 million (€9.4m) seed financing round and the appointment of Morten Graugaard as Independent Chair of its Board of Directors.
The round was led by Asabys, through its Sabadell Asabys II fund, with participation from CDTI with its SICC Innvierte and the Institut Català de Finances (ICF).
The company says the proceeds will be used to scale and expand ALLOX’s platform capabilities and to develop proprietary AI models that predict therapeutic hotspots from the company’s large, function-first biophysical datasets, accelerating the discovery of selective allosteric modulators of protein-protein interactions and transcription factors.
The financing will also strengthen ALLOX’s internal drug discovery team as it advances multiple drug discovery programmes towards a focused pipeline of proprietary small-molecule assets.
Morten Graugaard brings more than 20 years of experience across life sciences venture investing, R&D, business development and M&A, as well as building, scaling and running biotech companies. He is currently Chief Business Officer of Orbis Medicines, an AI-first oral biologics company he was instrumental in building and scaling. Previously, he was a Partner and Investment Director at Novo Holdings.
As Director of Corporate Development at Lundbeck, he led the company’s successful $658 million acquisition of Chelsea Therapeutics and was a key member of the deal team that negotiated a $1.8 billion global alliance with Otsuka Pharmaceutical.
Júlia Domingo, Chief Executive Officer and Co-Founder of ALLOX, said: “By combining large-scale functional data with predictive AI, we aim to unlock a much broader range of challenging drug targets and accelerate the discovery of truly differentiated small-molecule therapeutics. Morten’s guidance and leadership, along with the support of our investors, will be instrumental in advancing our programmes and maximising the long-term potential of our platform.”
